Novo Nordisk has seen its shares plummet after its experimental obesity drug CagriSema performed worse than the company expected. Patients taking the drug lost an average of 22.7% of their weight, which was below the expected 25%. This result led to a drastic drop in the market value of the company, which lost approximately $125 billion.
CagriSema is a combination of semaglutide, the active ingredient in Weg's drug, and cagrilintide, which mimics the hormone amylin in the pancreas. The drug was intended to be a stronger competitor to other obesity drugs such as Eli Lilly's Zepbound. While CagriSema achieved significant weight loss, it fell short of the company's stated goal. This result led to a 20% drop in Novo Nordisk's $NVOstock , resulting in a loss of $125 billion in market value for the company. This development raised concerns about the company's ability to develop a successful successor to Wegova, its most successful weight loss drug to date.
Competition and future prospects
Follo…